Jill Campbell Stewart1, Steven C Cramer. 1. Physical Therapy Program (J.C.S.), Department of Exercise Science, University of South Carolina, Columbia; and Departments of Neurology, Anatomy & Neurobiology, and Physical Medicine & Rehabilitation (S.C.C.), University of California, Irvine.
Abstract
BACKGROUND AND PURPOSE: In many neurologic diagnoses, significant interindividual variability exists in the outcomes of rehabilitation. One factor that may impact response to rehabilitation interventions is genetic variation. Genetic variation refers to the presence of differences in the DNA sequence among individuals in a population. Genetic polymorphisms are variations that occur relatively commonly and, while not disease-causing, can impact the function of biological systems. The purpose of this article is to describe genetic polymorphisms that may impact neuroplasticity, motor learning, and recovery after stroke. SUMMARY OF KEY POINTS: Genetic polymorphisms for brain-derived neurotrophic factor (BDNF), dopamine, and apolipoprotein E have been shown to impact neuroplasticity and motor learning. Rehabilitation interventions that rely on the molecular and cellular pathways of these factors may be impacted by the presence of the polymorphism. For example, it has been hypothesized that individuals with the BDNF polymorphism may show a decreased response to neuroplasticity-based interventions, decreased rate of learning, and overall less recovery after stroke. However, research to date has been limited and additional work is needed to fully understand the role of genetic variation in learning and recovery. RECOMMENDATIONS FOR CLINICAL PRACTICE: Genetic polymorphisms should be considered as possible predictors or covariates in studies that investigate neuroplasticity, motor learning, or motor recovery after stroke. Future predictive models of stroke recovery will likely include a combination of genetic factors and other traditional factors (eg, age, lesion type, corticospinal tract integrity) to determine an individual's expected response to a specific rehabilitation intervention.
BACKGROUND AND PURPOSE: In many neurologic diagnoses, significant interindividual variability exists in the outcomes of rehabilitation. One factor that may impact response to rehabilitation interventions is genetic variation. Genetic variation refers to the presence of differences in the DNA sequence among individuals in a population. Genetic polymorphisms are variations that occur relatively commonly and, while not disease-causing, can impact the function of biological systems. The purpose of this article is to describe genetic polymorphisms that may impact neuroplasticity, motor learning, and recovery after stroke. SUMMARY OF KEY POINTS: Genetic polymorphisms for brain-derived neurotrophic factor (BDNF), dopamine, and apolipoprotein E have been shown to impact neuroplasticity and motor learning. Rehabilitation interventions that rely on the molecular and cellular pathways of these factors may be impacted by the presence of the polymorphism. For example, it has been hypothesized that individuals with the BDNF polymorphism may show a decreased response to neuroplasticity-based interventions, decreased rate of learning, and overall less recovery after stroke. However, research to date has been limited and additional work is needed to fully understand the role of genetic variation in learning and recovery. RECOMMENDATIONS FOR CLINICAL PRACTICE: Genetic polymorphisms should be considered as possible predictors or covariates in studies that investigate neuroplasticity, motor learning, or motor recovery after stroke. Future predictive models of stroke recovery will likely include a combination of genetic factors and other traditional factors (eg, age, lesion type, corticospinal tract integrity) to determine an individual's expected response to a specific rehabilitation intervention.
Authors: Kenneth Blum; Amanda L C Chen; John Giordano; Joan Borsten; Thomas J H Chen; Mary Hauser; Thomas Simpatico; John Femino; Eric R Braverman; Debmalya Barh Journal: J Psychoactive Drugs Date: 2012 Apr-Jun
Authors: Winston D Byblow; Cathy M Stinear; P Alan Barber; Matthew A Petoe; Suzanne J Ackerley Journal: Ann Neurol Date: 2015-11-17 Impact factor: 10.422
Authors: Matthew J Gallek; Yvette P Conley; Paula R Sherwood; Michael B Horowitz; Amin Kassam; Sheila A Alexander Journal: Biol Res Nurs Date: 2008-11-17 Impact factor: 2.522
Authors: Helena Hybbinette; Ellika Schalling; Jeanette Plantin; Catharina Nygren-Deboussard; Marika Schütz; Per Östberg; Påvel G Lindberg Journal: Front Neurol Date: 2021-03-31 Impact factor: 4.003